NCT03787225 is a Phase 1 clinical trial of NNC0174-0833 in Obesity, sponsored by Novo Nordisk A/S.

Who is sponsoring NCT03787225?

NCT03787225 is sponsored by Novo Nordisk A/S.

What drugs are being tested in NCT03787225?

Interventions in NCT03787225: NNC0174-0833, Placebo (NNC0174-0833).

What condition does NCT03787225 study?

NCT03787225 studies Obesity, Overweight.

Is NCT03787225 still recruiting?

NCT03787225 is currently completed. Last updated 24 June 2019.

Last reviewed 2019-06-24 · How we verify

NCT03787225

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Research Study of How NNC0174-0833 Behaves in Japanese and Caucasian Volunteers Who Are Normal Weight, Overweight or With Obesity

Completed Phase 1 Last updated 24 June 2019

What this trial tests

Phase 1 trial testing NNC0174-0833 in Obesity in 66 participants. Completed in 4 June 2019.

Timeline

7 January 2019

Primary endpoint
4 June 2019

4 June 2019

Quick facts

Lead sponsor	Novo Nordisk A/S
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	66
Start date	7 January 2019
Primary completion	4 June 2019
Estimated completion	4 June 2019
Sites	1 location across United States

Drugs / interventions tested

NNC0174-0833 — full drug profile →
Placebo (NNC0174-0833)

Conditions studied

Obesity — all drugs for Obesity →
Overweight — all drugs for Overweight →

Sponsor

Novo Nordisk A/S — full company profile →

Who can join

Eligibility, male only, with Obesity or Overweight. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of this study is to look at how the study medicine behaves in the participant's body and how it is removed from the participant's body. The study compares Japanese and Caucasian people who are normal weight, overweight or with obesity. The participants will either get NNC0174-0833 (a potential new medicine) or placebo (a "dummy" medicine similar to the study medicine but without active ingredients) - which treatment any participant gets is decided by chance. Participants will get 1 injection by a study nurse at the clinic. The injection will be with a needle in a skin fold in the participant's stomach area. The study will last for about 4 months, but duration of participation for any participant will last up to about 2 months. The participants will have 8 clinic visits with the study staff.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of NNC0174-0833

Trials testing the same drug.

NCT04209049 — A Research Study Looking Into Blood Levels of NNC0174-0833 in People With Normal and Impaired Kidney Function · Phase 1 · completed
NCT04074174 — Research Study to Investigate the Effect of NNC0174-0833 on a Birth Control Pill in Women Who Are Not Able to Become Pre · Phase 1 · completed
NCT03856047 — Research Study Investigating How Well NNC0174-0833 Works in People Suffering From Overweight or Obesity. · Phase 2 · completed
NCT03600480 — A Research Study of How NNC0174-0833 Taken With Semaglutide Works in People Who Are Overweight or Obese · Phase 1 · completed
NCT02958085 — Investigation of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Dosing of NNC0174-0833 in Subje · Phase 1 · completed

Other recruiting trials for Obesity

Currently open trials in the same condition.

NCT07403604 — Effect of Insulin Lowering on Lipogenesis · Phase 1 · recruiting
NCT07509307 — AMAZE 6: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee · Phase 3 · recruiting
NCT07272837 — Impact of Semaglutide (Ozempic/Wegovy®) on Heart and Muscle Mass · recruiting
NCT07481630 — A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoart · Phase 3 · recruiting
NCT07527195 — Understanding the Effect of CagriSema, Cagrilintide, and Semaglutide on Muscle Health (Role of Amylin Signature in Muscl · Phase 1 · recruiting

Other Novo Nordisk A/S trials

Trials by the same sponsor.

NCT07357740 — A Research Study to Compare Two Different Versions of Injectable CagriSema in People With Type 2 Diabetes · Phase 2 · not yet recruiting
NCT07282613 — A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in Children and Adoles · Phase 3 · not yet recruiting
NCT07357766 — A Research Study to Compare Different Versions of Injectable CagriSema and Placebo in People With Excess Body Weight · Phase 3 · not yet recruiting
NCT07564414 — A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obe · Phase 3 · not yet recruiting
NCT07400107 — AMAZE 8: A Research Study Investigating How Well the Medicine NNC0487-0111 Compared to Semaglutide Helps People With Exc · Phase 3 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03787225 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Novo Nordisk A/S
Last refreshed: 24 June 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03787225.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing